Key result
Aprocitentan reduces office SBP by ~4 mm Hg vs. placebo in resistant hypertension.
Why the study?
Does aprocitentan reduce office systolic blood pressure in patients with resistant hypertension?
Does aprocitentan reduce office systolic blood pressure in patients with resistant hypertension?
Aprocitentan, the first approved dual endothelin receptor antagonist, significantly reduces systolic blood pressure in patients with resistant hypertension.
Answers are grounded in this paper and cite their sources.
May support aprocitentan in resistant hypertension; leaves open long-term outcomes and generalizability.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Powell et al. (2026) conducted a review in resistant hypertension. Aprocitentan vs. placebo was evaluated on mean change in office systolic blood pressure (MD -3.8 mm Hg, 95% CI -6.8 to -0.8). Aprocitentan reduced office systolic blood pressure at 4 weeks by a mean difference of -3.8 mm Hg compared to placebo in patients with resistant hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: